Edmond de Rothschild Equity Strategies IV (ERES IV), advised by Elyan Partners, has completed the acquisition of a majority stake in CRO Oncodesign Services first announced earlier in the year. The fund manager has taken 61.58% of Oncodesign Services’ share capital from its main shareholders shareholders, including founder Philippe Genne as well as certain reference…
Home Healthcare Markets International News France: ERES IV takes controlling block in Oncodesign Services and will file...